ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ: INHX) announced today that three posters describing preclinical data on INX-189, the Company’s nucleotide polymerase inhibitor in clinical development for the treatment of chronic hepatitis C (HCV) infections, will be presented by various scientists from the Company at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. The full abstracts can be viewed at the AASLD website at www.aasld.org.
